Schizophrenia/Psychosis

A new study reveals the overwhelming financial and emotional burdens faced by caregivers of individuals with schizophrenia, highlighting urgent support needs.

New research highlights the effectiveness of early psychosis intervention programs, emphasizing low caseloads and clozapine access to reduce relapse rates.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

Exploring the prevalence and implications of psychotropic polypharmacy in patients taking clozapine with treatment-resistant schizophrenia.

Care partners for patients with schizophrenia can greatly benefit from psychoeducation provided by clinicians.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Dive into the forms of assessment for cognitive dysfunction in relation to the diagnosis and treatment of schizophrenia.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.

Nearly half of catatonia patients relapse within two years, highlighting the need for effective long-term management strategies and potential benefits of antipsychotics.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

UK study of "active ingredients" in early psychosis intervention is applicable to US programs, according to the codirector of Stanford's INSPIRE Clinic.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Extreme heat poses serious health risks, especially for vulnerable populations. Learn essential tips to help patients stay safe during heat waves and protect their well-being.

Learn more about effective strategies for managing obesity and metabolic dysfunction in schizophrenia, focusing on dietary interventions and pharmacological treatments.

Panelists discuss how clinicians can better identify subtle and unreported schizophrenia symptoms through systematic evaluation of positive symptoms, negative symptoms, cognitive deficits, and functional impairment, which often requires input from family members and caregivers.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.